GHK-Cu
- Category
- Skin & Cosmetic
- Administration routes
- InjectableTopical
- Regulatory status
- Not FDA-approved
The copper-bound form of the GHK tripeptide, marketed for skin rejuvenation, wound healing, hair growth, and tissue repair. The strongest cases, skin and wound healing, rest mostly on topical and lab studies with thin human data, while hair growth, neuroprotection, and DNA repair are speculative. Injectable research-grade supply is unregulated and of uncertain purity, and best avoided in Wilson disease and copper allergy. Not an approved drug in the US.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
GHK-Cu is a naturally occurring copper-peptide complex found in human blood, first isolated from plasma in 1973. Made of just three amino acids bound to a copper ion, it plays a key role in tissue remodeling, wound healing, and skin regeneration. GHK-Cu levels decline roughly 60% as you age, dropping from about 200 mcg/L in young adults to around 80 mcg/L by age 60-80. It is one of the most widely studied peptides in skin care and anti-aging, known for stimulating collagen and elastin production.
How it works in the body
The copper-bound form of GHK tripeptide. Copper delivery activates lysyl oxidase (needed for collagen crosslinking) and superoxide dismutase (antioxidant defense). The peptide itself signals through integrins on cell surfaces to promote wound healing, collagen synthesis, and tissue remodeling.
Research overview
GHK-Cu works by influencing the expression of roughly 4,000 human genes — about 31% of the genome — switching on repair and regeneration programs while dialing down inflammatory ones. It stimulates the production of collagen, elastin, and structural molecules in skin and connective tissue, promotes the growth of new blood vessels at injury sites, and supports nerve regrowth. It also activates 47 DNA repair genes and boosts the body's own antioxidant defenses by increasing superoxide dismutase (SOD) activity. When tissue is injured, GHK-Cu is naturally released from collagen breakdown, acting as a biological signal to begin the repair process. Research spans hundreds of studies, primarily in cell culture and animal models, with limited controlled human trials — most human evidence comes from topical skin care applications rather than systemic use.
Who researches GHK-Cu?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching skin health and rejuvenation
Studied for collagen synthesis, skin repair, or anti-aging skin effects.
People researching hair restoration options
Explored for effects on hair follicle stimulation or hair regrowth.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
Important considerations for
Those with Wilson's disease
AbsoluteCopper accumulation disorder. Additional copper delivery is dangerous.
Those with Active cancer
ModerateGHK-Cu stimulates blood vessel growth and cell proliferation, which may promote tumor growth.
Those with Copper sensitivity/allergy
HighContains copper. Can cause local reactions in sensitive individuals.
Safety & interactions
Do not use if
Wilson's disease
AbsoluteCopper accumulation disorder. Additional copper delivery is dangerous.
Copper sensitivity/allergy
HighContains copper. Can cause local reactions in sensitive individuals.
Active cancer
ModerateGHK-Cu stimulates blood vessel growth and cell proliferation, which may promote tumor growth.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(5)
Rated by level of concern
Contraindicated in Wilson disease (genetic copper overload)
ModerateWilson disease copper pathophysiology; GHK-Cu copper-delivery mechanism (PMC6073405)
Contraindicated in copper allergy
ModerateCopper contact-allergy dermatology literature
Insufficient safety data for pregnancy/breastfeeding
ModerateNo pregnancy/lactation trials indexed (data gap)
Injectable forms unregulated; quality risks
HighFDA regulatory status (not an approved drug)
Long-term systemic effects of exogenous copper peptide not fully studied
ModerateAbsence of long-term human systemic safety studies
Interaction summary(6)
Rated by direction with this peptide
Copper-chelating drugs (penicillamine, trientine)
CautionModerateGHK-Cu supplies bioavailable copper and could directly oppose copper-chelation therapy used in Wilson disease/copper overload, so it should be avoided in patients on these agents.
Chelator pharmacology + GHK-Cu copper-delivery mechanism (PMC6073405)
Oral copper supplements / high-copper intake
CautionLowAdditive copper exposure is theoretically possible with systemic GHK-Cu use, favoring avoidance of concurrent copper loading; topical exposure is minimal.
Mechanism-based (copper additivity)
Zinc supplements (high-dose)
CautionTheoreticalZinc and copper compete for absorption, so chronic high-dose zinc could shift copper balance and theoretically blunt or complicate GHK-Cu's copper delivery.
Zinc-copper antagonism (nutritional physiology)
Topical vitamin C (L-ascorbic acid)
CautionLowCo-application with acidic ascorbic acid can drive redox reactions that degrade the copper-peptide complex (and may oxidize the vitamin C), so products are usually separated in time.
Formulation-stability guidance (cosmetic chemistry)
Topical AHA/BHA and other low-pH actives
CautionLowA strongly acidic environment can destabilize the Cu-peptide bond, reducing efficacy; alternating rather than layering is advised.
Formulation-stability guidance (cosmetic chemistry)
Topical retinoids (tretinoin/retinol)
SynergisticTheoreticalComplementary collagen-stimulating pathways make combination plausibly additive for photoaging, and GHK-Cu is generally well tolerated, though combined use can increase irritation.
Mechanism-based (collagen stimulation); Miller 2006 tolerability context
Known risks(5)
Contraindicated in Wilson disease (genetic copper overload)
Contraindicated in copper allergy
Insufficient safety data for pregnancy/breastfeeding
Injectable forms require prescription — unregulated sources carry quality risks
Long-term systemic effects of exogenous copper peptide supplementation not fully studied
Drug interactions(3)
BPC-157
Both promote tissue repair through different mechanisms. Complementary wound healing.
TB-500
GHK-Cu acts on ECM remodeling and TB-500 on cell migration.
Copper supplements
GHK-Cu delivers copper. Concurrent copper supplementation could lead to excess.
Research & benefits
Evidence base
- Evidence Level
- Limited Clinical
- Total Studies
- 81
- Human Studies
- 12
Multiple placebo-controlled studies confirm wrinkle reduction, skin improvement. RCT (n=40): 55.8% wrinkle volume reduction. Finkley (n=67): improvements across all skin parameters. Miller RCT: no significant objective post-laser benefit; patient-reported satisfaction was higher. Human safety evidence is limited, particularly for injections.
Researched for(7)
Rated by confidence in the evidence
Skin rejuvenation
MediumSmall human studies show collagen induction and reduced wrinkle volume, with mixed objective results.
Abdulghani AA et al., Dis Manag Clin Outcomes 1998;1(4):136-141 (procollagen 7/10 subjects); Miller TR et al., Arch Facial Plast Surg 2006;8(4):252, PMID 16847171 (CO2 laser resurfacing - objectively negative, subjective satisfaction only); review PMC8789089
Wound healing
MediumThe 64.5% versus 28.2% result came from rats. Human topical wound evidence is limited; post-laser objective outcomes were negative.
Canapp et al., Vet Surg 2003, PMID 14648529 (rat percentage result); Mulder et al., PMID 17147644 (human diabetic ulcers); Miller et al., PMID 16847171 (negative objective post-laser results).
Anti-inflammatory/antioxidant
LowBoosts antioxidant enzymes and cuts lipid peroxidation, but evidence is largely lab-based.
Review PMC8789089 (Zhou 2017, Park 2016); Pickart & Margolina 2018 PMC6073405
Hair growth
SpeculativeA small 2026 randomized split-face study reported improved eyebrow hair count and diameter in 18 participants; scalp efficacy remains uncertain.
Bo et al., Procedia of Multidisciplinary Research, May 2026: randomized, double-blind, vehicle-controlled split-face eyebrow study, n=18.
Neuroprotection
SpeculativeStimulates nerve growth factors and gene expression in animal and cell studies only.
Pickart & Margolina 2018 PMC6073405; review PMC8789089 (aged-mouse learning)
DNA repair
SpeculativeGene-expression studies show activation of DNA repair genes; preliminary lab findings only.
Pickart, Vinski & Margolina, J Analyt Oncol 2014 (DNA repair gene induction); PMC6073405
Musculoskeletal repair
LowImproved ligament healing in a rat model, with matrix remodeling shown in animals.
Review PMC8789089 (Fu 2015 ACL; Godet & Marie 1995; Pohunkova 1996)
Benefits(7)
Skin rejuvenation
Wound healing
Anti-inflammatory/antioxidant
Hair growth
Neuroprotection
DNA repair
Musculoskeletal repair
Key studies(5)
Pickart L, Margolina A
Int J Mol Sci
2018
GHK regulates 31.2% of human genes. Broad regenerative, anti-inflammatory, anti-cancer effects.
Pickart L et al.
BioMed Res Int
2015
Regulates 4,000+ genes. Tightens skin, improves elasticity, reduces wrinkles and photodamage.
Pickart L et al.
Oxid Med Cell Longev
2012
Increases SOD, reduces lipid peroxidation 75%, stimulates nerve outgrowth, modulates 435 genes
Pickart L et al.
Brain Sciences
2017
700+ nerve-related genes modified. 47 DNA repair, 41 ubiquitin-proteasome genes activated.
Miller TR et al.
Arch Facial Plast Surg
2006
RCT with 13 completers: no significant improvement in erythema resolution, wrinkles or objective skin quality; satisfaction was higher.
What research suggests over time
Weeks 2-4
Topical RCTsTopical: improved skin texture, reduced fine lines, and brighter complexion in multiple human RCTs.
Months 2-3
Topical RCTsCollagen synthesis upregulation; accelerated wound healing observed in clinical trials of GHK-Cu creams.
Long-term
Topical RCTs / preclinical injectableInjectable GHK-Cu nominations were withdrawn; FDA still identifies potential safety risks and limited human safety data.
Regulation & availability
Why researchers look at it
This tiny copper peptide modulates roughly 4,000 human genes — activating 47 DNA repair pathways while suppressing inflammatory ones — and natural levels drop ~60% by old age. Placebo-controlled trials (n=40, n=67) confirmed 55.8% wrinkle volume reduction and broad skin parameter improvements. If systemic research catches up to the strong topical evidence, GHK-Cu could become a cornerstone of accessible age-related tissue repair.
- Estimated cost
- $30-80/mo topical (OTC cosmetic)
- FDA status
- GHK-Cu is not FDA-approved as a drug; it is a common cosmetic ingredient (copper tripeptide-1). For non-injectable use, FDA is evaluating it for its compounding list (Category 1), so pharmacies may compound it, for example as a cream, for an individual patient's prescription. Injectable GHK-Cu is not eligible for compounding. FDA plans to ask its advisory committee about GHK-Cu before the end of February 2027. Used in cosmetics as Copper Tripeptide-1.
- WADA status
- Not listed by WADA
- Prescribability
- GHK-Cu is not FDA-approved as a drug; it is a common cosmetic ingredient (copper tripeptide-1). For non-injectable use, FDA is evaluating it for its compounding list (Category 1), so pharmacies may compound it, for example as a cream, for an individual patient's prescription. Injectable GHK-Cu is not eligible for compounding. FDA plans to ask its advisory committee about GHK-Cu before the end of February 2027.
- Availability
- OTC topical skincare is available. Under the 503A interim policy, non-injectable GHK-Cu has conditional Category 1 coverage; injectable GHK-Cu does not.
International status
EU
Available OTC in cosmetics (INCI listed)
UK
Available OTC in cosmetics
US
GHK-Cu is not FDA-approved as a drug; it is a common cosmetic ingredient (copper tripeptide-1). For non-injectable use, FDA is evaluating it for its compounding list (Category 1), so pharmacies may compound it, for example as a cream, for an individual patient's prescription. Injectable GHK-Cu is not eligible for compounding. FDA plans to ask its advisory committee about GHK-Cu before the end of February 2027.
Canada
Available OTC in cosmetics
Australia
Available OTC in cosmetics
Regulatory timeline(3)
- 1973DiscoveryIsolated from human plasma by Loren Pickart
- 2023-09FDA Category 2Injectable form restricted from compounding
- 2025FDA warning lettersCompanies making unapproved drug claims about GHK-Cu skincare
Sources & FAQs
Research sources(5)
- Regenerative and Protective Actions of GHK-Cu in Light of New Gene Data
- GHK Peptide as Natural Modulator of Multiple Cellular Pathways in Skin Regenerat
- GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions
- GHK Gene Expression Relevant to Nervous System and Cognitive Decline
- Topical Copper Tripeptide on CO2 Laser-Resurfaced Skin
Frequently asked questions(4)
Is it safe?
Human safety evidence is limited, particularly for injections; FDA identifies potential immunogenicity and peptide-impurity risks. Contraindicated in Wilson disease and copper allergy.
Topical vs injectable?
Topical acts locally on skin (OTC). Injectable provides systemic effects: anti-inflammatory, tissue repair, neuroprotection, hair growth. Injectable GHK-Cu is not eligible for compounding: it is excluded from 503A Category 1, and FDA lists it among withdrawn nominations that may present significant safety risks.
Why does it decline with age?
Plasma levels fall by more than half between youth and age 60-80. The decline correlates with decreased wound healing, collagen synthesis and tissue regeneration.
Hair loss?
Preclinical data show up to 50% follicle enlargement and Wnt/beta-catenin activation. A reported 26.5% median top-scalp-area regrowth came from seven patients receiving minoxidil, dutasteride and copper peptides by tattoo delivery, without a control group; GHK-Cu's contribution was not isolated. No large-scale monotherapy RCTs yet.